Literature DB >> 1705737

G-CSF and GM-CSF in clinical trials.

K H Antman1.   

Abstract

Hematopoietic growth factors have now been purified, cloned, and produced in bacteria and yeast. Those that are currently in clinical study include erythropoietin, GM-CSF, G-CSF, M-CSF (also called CSF-1), and multi-CSF (also called interleukin 3). Growth factor appear likely to enhance the recovery and function of circulating white cells after standard-dose cancer therapy and high-bone-dose cancer therapy with marrow transplant and to restore leukocyte numbers and competence in the acquired immune deficiency syndromes and myelodysplastic syndromes. Phase I, II trials in AIDS, in cancer patients receiving chemotherapy, in cases of myeloproliferative disease, and after bone marrow transplant have been published. The results of phase III studies are just becoming available.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1705737      PMCID: PMC2589368     

Source DB:  PubMed          Journal:  Yale J Biol Med        ISSN: 0044-0086


  106 in total

1.  Effect of recombinant human granulocyte-macrophage colony-stimulating factor on the hemopoietic progenitor cells from patients with AIDS.

Authors:  A Ganser; B Völkers; J Greher; D Hoelzer
Journal:  Behring Inst Mitt       Date:  1988-08

2.  The effects of recombinant human granulocyte-macrophage colony-stimulating factor on phagocyte kinetics in man.

Authors:  D C Linch; S Devereux; I E Addison
Journal:  Behring Inst Mitt       Date:  1988-08

3.  A phase I study of therapy with recombinant granulocyte-macrophage colony-stimulating factor administered by IV bolus or continuous infusion.

Authors:  R M Rifkin; E M Hersh; S E Salmon
Journal:  Behring Inst Mitt       Date:  1988-08

4.  In vitro and in vivo action of recombinant human GM-CSF (rhGM-CSF) in patients with myelodysplastic syndromes.

Authors:  D Hoelzer; A Ganser; B Völkers; J Greher; F Walther
Journal:  Blood Cells       Date:  1988

5.  Use of recombinant human granulocyte-macrophage colony-stimulating factor in autologous marrow transplantation for lymphoid malignancies.

Authors:  J Nemunaitis; J W Singer; C D Buckner; R Hill; R Storb; E D Thomas; F R Appelbaum
Journal:  Blood       Date:  1988-08       Impact factor: 22.113

6.  Neutrophil migration is defective during recombinant human granulocyte-macrophage colony-stimulating factor infusion after autologous bone marrow transplantation in humans.

Authors:  W P Peters; A Stuart; M L Affronti; C S Kim; R E Coleman
Journal:  Blood       Date:  1988-10       Impact factor: 22.113

7.  Phase I/II study of recombinant human granulocyte-macrophage colony-stimulating factor in aplastic anemia and myelodysplastic syndrome.

Authors:  J H Antin; B R Smith; W Holmes; D S Rosenthal
Journal:  Blood       Date:  1988-08       Impact factor: 22.113

8.  Stimulation of hematopoiesis in patients with bone marrow failure and in patients with malignancy by recombinant human granulocyte-macrophage colony-stimulating factor.

Authors:  S Vadhan-Raj; S Buescher; A LeMaistre; M Keating; R Walters; C Ventura; W Hittelman; H E Broxmeyer; J U Gutterman
Journal:  Blood       Date:  1988-07       Impact factor: 22.113

9.  Recombinant granulocyte-macrophage colony-stimulating factor improves hematopoietic recovery after 5-fluorouracil.

Authors:  M O'Reilly; R L Gamelli
Journal:  J Surg Res       Date:  1988-07       Impact factor: 2.192

10.  Hemopoietic colony growth-promoting activities in the plasma of bone marrow transplant recipients.

Authors:  K Yamasaki; L A Solberg; N Jamal; G Lockwood; D Tritchler; J E Curtis; M M Minden; K G Mann; H A Messner
Journal:  J Clin Invest       Date:  1988-07       Impact factor: 14.808

View more
  3 in total

1.  Treatment of neutropenia in Felty's syndrome with granulocyte-macrophage colony-stimulating factor--hematological response accompanied by pulmonary complications with lethal outcome.

Authors:  A R Gari-Bai; C Rochlitz; M Riewald; J Oertel; D Huhn
Journal:  Ann Hematol       Date:  1992-11       Impact factor: 3.673

2.  Recombinant Granulocyte-Macrophage Colony-Stimulating Factor (rGM-CSF) : A Review of its Pharmacological Properties and Prospective Role in the Management of Myelosuppression.

Authors:  Susan M Grant; Rennie C Heel
Journal:  Drugs       Date:  1992-04       Impact factor: 9.546

3.  Good Manufacturing Practice-Grade of Megakaryocytes Produced by a Novel Ex Vivo Culturing Platform.

Authors:  Xin Guan; Lan Wang; Hanlu Wang; Huihui Wang; Wei Dai; Yongping Jiang
Journal:  Clin Transl Sci       Date:  2020-10-08       Impact factor: 4.689

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.